Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders, primarily affecting the pulmonary interstitium. These disorders are characterized by fibrosis, inflammation, or a combination of both. ILDs are often complex, requiring a comprehensive understanding of their causes, symptoms, and treatment options.
ILDs can be idiopathic or associated with a myriad of causes, such as connective tissue diseases, occupational and environmental exposures, drugs, and radiation. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic ILD, with a poorly understood etiology. It is believed that genetic predisposition, aging, and environmental factors like smoking contribute to the development of IPF.
ILDs typically present with insidious onset of dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, showing characteristic patterns such as reticular opacities, honeycombing, and ground-glass opacities. Pulmonary function tests often reveal a restrictive pattern with reduced diffusion capacity.
Management of ILDs depends on the underlying cause. In cases of IPF, antifibrotic agents like pirfenidone and nintedanib have shown to slow disease progression. For ILDs associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation remains the ultimate treatment for selected patients with advanced disease.
ILDs are a diverse group of lung disorders with varying etiologies and clinical presentations. A thorough understanding of the causes, symptoms, and treatment options is essential for optimal patient management. Future research should focus on elucidating the pathogenesis of idiopathic ILDs and developing novel therapeutic strategies.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation